SCHEMBL40427

SCHEMBL40427

CCN1CCCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22081189 0.93
SCHEMBL2754687 0.84
SCHEMBL11352325 0.81
SCHEMBL64647 0.80
SCHEMBL6330683 0.79 PDK1 (0.32)
SCHEMBL9892711 0.78
SCHEMBL11123840 0.78 SIGMAR1 (0.39)
SCHEMBL15996236 0.76 GNAI3 (0.41)
SCHEMBL24801781 0.75
SCHEMBL8527305 0.75 KMT2A (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240393298-A1 MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM PHENOMENEX, INC. (US) 2024-11-28 US disclosed
WO-2024091409-A1 TRICYCLIC DERIVATIVES AS KRAS INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
WO-2024008941-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2024-01-11 WO disclosed
US-20230322816-A1 PYRAZOLE BORONIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES THEREOF BEIJING SONGRUN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-10-12 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
WO-2020132653-A1 HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS AMGEN INC. (US) 2020-06-25 WO disclosed
WO-2020117972-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-06-11 WO disclosed
US-10647678-B2 Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-12 US disclosed
US-20180170944-A1 USE OF THE FL-ONE HUNDRED EIGHTEEN CORE CHEMICAL STRUCTURE PLATFORM TO GENERATE FL-ONE HUNDRED EIGHTEEN DERIVATIVES FOR TREATMENT OF HUMAN DISEASE CANGET BIOTEKPHARMA, LLC (US) 2018-06-21 US disclosed
US-20180093955-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-04-05 US disclosed
US-9139613-B2 Macrocyclic compounds and methods for their production NEUROVIVE PHARMACEUTICAL AB (SE) 2015-09-22 US disclosed
US-20140038885-A1 Macrocyclic Compounds and Methods for Their Production NEUROVIVE PHARMACEUTICAL AB (SE) 2014-02-06 US disclosed
US-20120295841-A1 Sanglifehrin Based Compounds Abliva Ab (SE) 2012-11-22 US disclosed
US-20110056779-A1 HIGH PERFORMANCE ADHESIVES AND METHODS FOR THEIR USE HENKEL CORPORATION (US) 2011-03-10 US disclosed
US-20110053925-A1 Hydroxamate-Based Inhibitors of Deacetylases NOVARTIS AG 2011-03-03 US disclosed
US-7517925-B2 Benzoxazines, thermosetting resins comprised thereof, and methods for use thereof HENKEL CORPORATION (US) 2009-04-14 US disclosed